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share the work provObjectives: Despite successful antiretroviral therapy, people living with HIV (PLWH)
may show signs of premature/accentuated aging. We compared established biomarkers
of aging in PLWH, appropriately chosen HIV-negative individuals, and blood donors,
and explored factors associated with biological age advancement.
Design: Cross-sectional analysis of 134 PLWH on suppressive antiretroviral therapy, 79
lifestyle-comparable HIV-negative controls aged 45 years or older from the Co-mor-
Bidity in Relation to AIDS (COBRA) cohort, and 35 age-matched blood donors.
Methods: Biological age was estimated using a validated algorithm based on 10
biomarkers. Associations between ‘age advancement’ (biological minus chrono-
logical age) and HIV status/parameters, lifestyle, cytomegalovirus (CMV), hepatitis
B (HBV) and hepatitis C virus (HCV) infections were investigated using linear regres-
sion.
Results: The average (95% CI) age advancement was greater in both HIV-positive [13.2
(11.6–14.9) years] and HIV-negative [5.5 (3.8–7.2) years] COBRA participants compared
with blood donors [7.0 (4.1 to 9.9) years, both P’s<0.001)], but also in HIV-positive
compared with HIV-negative participants (P<0.001). Chronic HBV, higher anti-CMV
IgG titer and CD8þ T-cell count were each associated with increased age advance-
ment, independently of HIV-status/group. Among HIV-positive participants, age
advancement was increased by 3.5 (0.1–6.8) years among those with nadir CD4þ
T-cell count less than 200 cells/ml and by 0.1 (0.06–0.2) years for each additional
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260 AIDS 2019, Vol 33 No 2Conclusion: Both treated PLWH and lifestyle-comparable HIV-negative individuals
show signs of age advancement compared with blood donors, to which persistent CMV,
HBV co-infection and CD8þ T-cell activation may have contributed. Age advancement
remained greatest in PLWH and was related to prior immunodeficiency and cumulative
saquinavir exposure. Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc.AIDS 2019, 33:259–268Keywords: accelerated aging, aging, biological age, biomarkers of aging, HIV,
premature agingIntroduction
Despite the success of combination antiretroviral therapy,
people living with HIV (PLWH) have an increased
burden of noncommunicable age-associated comorbid-
ities compared with HIV-negative individuals [1,2]. The
causes of this increased burden of comorbidities remain
unclear but may involve an accelerated or accentuated
aging process [3,4], resulting from a complex mix of
HIV infection, antiretroviral treatment, chronic viral
co-infections and lifestyle/behavioral factors.
Aging can be defined as the time-dependent decline of
functional capacity and stress resistance associated with
increased risk of disability, morbidity and mortality [5].
There is clear evidence that the rate of aging differs
significantly between individuals, because of genetic
heterogeneity and environmental factors [6]. Therefore,
chronological age may not represent the best way of
measuring aging and may not accurately reflect an
individual’s position in his/her total lifespan [7]. This has
led to a search for reliable biomarkers of aging, defined as
biological parameters that capture the age-related changes
in body function or composition. These biomarkers
could serve to measure ‘biological’ age, a hypothetical
value denoting the extent of age-related changes in
function and composition of a human body, and predict
the onset of age-related diseases and/or expectant residual
lifetime more accurately than chronological age [8].
Many candidate biomarkers of aging have been proposed
in the scientific literature and have been used to investigate
the association between HIVand aging [9]. Among these,
there are markers of chronic systemic immune activation
(soluble CD14þ and CD163þ [10,11]), inflammation
(C-reactive protein and interleukin-6 [12]), coagulation
(D-dimer [13]), leukocyte telomere length [14], somatic
mitochondrial DNA mutations [15], expression levels of
the cell cycle regulator CDKN2A [14], DNAmethylation
levels [16], ophthalmological parameters [17] and age-
related brain atrophy [18].
Combinations of biomarkers may more reliably measure
these age-related changes (or what is called also
‘biological age’), giving more accurate estimates of
residual lifetime than that obtained from any singlebiomarker in isolation. The MARK-AGE project has
proposed a method to combine powerful biomarkers of
human aging (most of which have been shown to be good
markers of age when taken in isolation [19,20]) to predict
biological age of individuals, and therefore, assess the
aging process [21,22].
The current study aimed to compare established
biomarkers of aging and their combination (as proposed
by the MARK-AGE study) in order to evaluate the
biological age of PLWH, demographically and lifestyle-
matched HIV-negative individuals, and blood donors
with similar chronological age. Furthermore, we investi-
gated the associations between any observed age
advancement and lifestyle risk factors, chronic viral co-
infections including hepatitis B virus (HBV), hepatitis C
virus (HCV) and cytomegalovirus (CMV), HIV-related
parameters and (cumulative) past or current exposure to
antiretroviral drugs.Methods
Study participants
HIV-positive (n¼ 134) and HIV-negative individuals
with similar sociodemographic and lifestyle factors
(n¼ 79) were prospectively enrolled in the COmorBidity
in Relation to AIDS (COBRA) cohort from HIV
outpatient clinics and sexual health centres, respectively,
located in Amsterdam (Netherlands) and London (UK)
[23]. Inclusion criteria were age 45 years or older (50
years in London), laboratory-confirmed presence or
absence of HIV-1 infection, and the HIV-positive people
were required to have plasma HIV-RNA less than
50 copies/ml for at least 12 months on antiretroviral
therapy. Exclusion criteriawere: current major depression
[as indicated by a Patient Health Questionnaire-9 (PHQ-
9) score 15 at screening], confounding neurological
diseases, previous severe head injury (with loss of
consciousness for 30 min), a history of cerebral
infections (including AIDS-defining diseases involving
the central nervous system), current intravenous drug use
(in the past 6 months, based on self-report), daily use of
recreational drugs (with the exception of cannabis),
excess alcohol intake (>48 units per week), severe
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lumbar puncture examination. Recruitment took place
between December 2011 and October 2014. The study
was approved by the institutional review board of the
Academic Medical Center (AMC) in Amsterdam
(reference number NL 30802.018.09) and a UK
Research Ethics Committee (REC) (reference number
13/LO/0584 Stanmore, London). All participants gave
written informed consent.
In addition, 35 blood donors were selected from the
Dutch national blood bank in Amsterdam, the
Netherlands (https://www.sanquin.nl/en/). Blood
donors were age-matched with the HIV-positive and
HIV-negative COBRA participants and, as a requirement
for blood donation in the Netherlands, they had screened
negative for HIV, HBV, HCV, syphilis, and human T-
lymphotropic virus 1 and 2 (HTLV) infections. Candidate
blood donors in the Netherlands are also eventually
excluded from blood donation based on a questionnaire
with regard to health (general and sexual), medication
use, sexual risk behavior and travel.Biomarkers of aging
A 10-item panel of biomarkers of aging identified by the
MARK-AGE project [21,22] were measured and are
listed in Supplementary Table 1, http://links.lww.com/
QAD/B389. Briefly, these biomarkers have been selected
as best predictors of chronological age among nearly 400
candidate biomarkers in a population of approximately
3300 individuals aged between 30 and 74 years (mean age
was 56 years) recruited from eight European countries.
Lycopene, and a-tocopherol in plasma were simulta-
neously determined by high performance liquid chro-
matography with UV and fluorescence detection as
previously described [24]. Alpha-2-macroglobulin in
plasma was measured on an autoanalyzer (DxC 800;
Beckman-Coulter, Woerden, The Netherlands) by an
immunoturbimetric method using reagents from Dialab,
Wiener Neudorf, Austria as described by Jansen et al.
[25]. Dehydroepiandrosterone sulfate, ferritin (women
only), and prostate-specific antigen (men only) in plasma
were analyzed using an immuno-analyzer (Access-2;
Beckman–Coulter) [25]. ELOVL2 and FHL2 DNA
methylation in purified PBMC were analyzed using the
Agena Bioscience’s EpiTYPER DNA methylation
analysis technology [26]. The N-glycans present on the
proteins in plasmawere released, labelled, and analyzed by
DSA-FACE technology, as described previously [20].Age advancement
The biological age of each individual was derived
separately for men and women as a linear combination
of these biomarkers using the method and the weights
described in Bu¨rkle et al. [22]. Age advancement for each
individual was then defined as the difference between
biological and chronological age. Positive ageadvancement is, therefore, indicative of more age-related
changes in body function and composition than what
would be expected in the average population, given the
observed chronological age; negative age advancement
would suggest less age-related changes.
Statistical analysis
Participants’ characteristics and distribution of the 10
biomarkers used to derive biological age are reported as raw
and relative frequencies or median and interquartile range
(IQR) and differences across groups were evaluated using
chi-square or Wilcoxon signed-rank tests, as appropriate.
Age advancement in each group is reported as mean and
95% confidence interval (CI) and assessed for significance
using the one-sample t-test. Differences between groups
were assessed using linear regressionwithHIV status/study
group as categorical independent variable.
Associations were considered between age advancement
and the following factors:(1) Sociodemographic factors (age, sex, ethnicity, sexuality,
years of education)(2) Self-reported smoking, alcohol consumption and
current recreational drug use(3) CMV (CMV serostatus, CMV total IgG and CMV
high-avidity IgG titers), chronic HBV (defined as
detectable hepatitis B surface antigen and/or HBV
DNA) and HCV (defined as detectable HCV RNA)(4) HIV disease parameters such as CD4þ and CD8þ T-cell
counts, CD4þ : CD8þ T-cell ratio, nadir CD4þ T-cell
count, nadir CD4þ T-cell count <200 cells/ml, years
since HIV diagnosis, prior AIDS diagnosis (defined as
prior category C event as per the Centers for Disease
Control and Prevention’s classification system for HIV
infection)(5) Exposure to antiretroviral drugs considered as both prior
exposure (yes or no) andmonths of cumulative exposure.The associations of age advancement with each factor,
unadjusted and adjusted for HIV status/study group, were
assessed through a series of linear regression models (with
each factor considered one at the time in separate models).
Factors that remained significantly associated with age
advancement after adjustment for HIV status and group
(P< 0.1), were then included in a multivariable regression
model to identify factors independently associatedwith age
advancement. All statistical analyses were performed using
SAS v9.4 (Cary, North Carolina, USA).Results
Cohort characteristics
The 79 HIV-negative COBRA participants were
comparable with the 134 HIV-positive participants in
terms of age, sex, years of education, smoking and
recreational drug use. HIV-positive participants were
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Table 1. Characteristics of the COBRA participants and blood donors (P1: HIV-positive vs. HIV-negative COBRA participants; P2: HIV-positive
COBRA participants vs. blood donors: both were obtained from chi-square or Wilcoxon signed-rank tests, as appropriate).
COBRA participants
n (%) or median (IQR) HIV-positive (n¼134) HIV-negative (n¼79) P1 Blood donors (n¼35) P2
Age (years) 55 (51–62) 57 (52, 64) 0.24 59 (52, 65) 0.37
Sex: female 9 (6.7%) 6 (7.6%) 0.79 17 (48.6%) <0.001
Male 125 (93.3%) 73 (92.4%) 18 (51.4%)
Ethnicity: black-African 16 (12.0%) 2 (2.6%) 0.03 n/a
White 117 (88.0%) 76 (97.4%) n/a
Sexuality: MSM 104 (77.6%) 59 (74.7%) 0.45 n/a
Bisexual 10 (7.5%) 4 (5.1%) n/a
Heterosexual 18 (13.4%) 16 (20.2%) n/a
Years of education 14 (13, 16) 16 (14, 17) 0.23 n/a
Smoking status: current smoker 40 (29.9%) 20 (25.3%) 0.24 n/a
Ex-smoker 58 (43.2%) 29 (36.7%) n/a
Never smoked 36 (26.9%) 30 (38.0%) n/a
Alcohol consumption: current drinker 104 (77.6%) 71 (89.9%) 0.04 n/a
Previous drinker 18 (13.4%) 3 (3.8%) n/a
Never drunk 12 (9.0%) 4 (5.1%) n/a
Recreational drugs use in past 6 months 44 (32.8%) 18 (22.8%) 0.16 n/a
Chronic HBV infection 7 (5.3%) 0 (0.0%) 0.05 0 (0.0%) 0.34
Chronic HCV infection 5 (3.7%) 0 (0.0%) 0.16 0 (0.0%) 0.58
CMV infection 129 (97.7%) 63 (79.8%) <0.001 8 (22.9%) <0.001
Total anti-CMV IgG (AU) 51.2 (29.0–107.0) 21.1 (11.8–53.8) <0.001 11.3 (10.2–16.8) 0.003
High avidity anti-CMV IgG (AU) 29.4 (14.9–61.1) 12.6 (7.2–25.3) <0.001 10.7 (10.0–13.2) 0.02
CD4þ T-cell count (cells/ml) 618 (472–806) 900 (692–1174) <0.001 n/a
CD8þ T-cell count (cells/ml) 770 (611– 947) 422 (313–614) <0.001 n/a
CD4þ : CD8þ T-cell count ratio 0.84 (0.60–1.12) 2.01 (1.44–2.64) <0.001 n/a
Nadir CD4þ T-cell count (cells/ml) 180 (90–250) n/a n/a
Years since HIV diagnosis 15.0 (9.1–20.0) n/a n/a
Duration of antiretroviral therapy (years) 12.5 (7.4–16.9) n/a n/a
Nadir CD4þ T-cell count less than 200 cells/ml 83 (61.9%) n/a n/a
Prior AIDS 42 (31.3%) n/a n/a
ARV, antiretroviral therapy; COBRA, Co-morBidity in Relation to AIDS; CMV, cytomegalovirus; HBV, hepatitis B virus; HCV, hepatitis C virus.more likely to be of black-African origin (P¼ 0.03) and
were less likely to report current alcohol consumption
(P¼ 0.04) than the HIV-negative participants. Compared
with both groups of COBRA participants, the blood
donor group included a greater proportion of women
(P< 0.001). CMV, chronic HBVand HCV co-infections
were all more frequent in HIV-positive COBRA
participants compared with both the HIV-negative
participants and blood donors, with CMV also being
more frequent in HIV-negative participants than in blood
donors. All HIV-positive COBRA participants had
plasma HIV RNA less than 50 copies/ml and were on
antiretroviral therapy at study visit, they had a median
(IQR)CD4þT-cell count of 618 (472–806) cells/ml, and
31% had a prior clinical AIDS diagnosis (Table 1). The
number and proportion of people who had ever been
exposed to each antiretroviral drug and the median (IQR)
duration of exposure are reported in Supplementary
Table 2, http://links.lww.com/QAD/B389.
Biomarkers of aging
The distribution of each of the 10 biomarkers of aging
used to derive biological age is summarized in
Supplementary Table 3, http://links.lww.com/QAD/
B389. HIV-positive COBRA participants had a greater
cumulative proportion of cytosine methylation at four outof five gene positions compared with HIV-negative
COBRA participants (all P’s 0.01). DHEAS and A2M
(in male participants only) concentrations were also
significantly different in the two COBRA groups
(P¼ 0.03 and P¼ 0.004, respectively). In all the five
gene positions, the cumulative proportion of cytosine
methylation in blood donors was significantly lower than
that seen in both COBRA groups. A2M concentration
(in males only) in blood donors was lower compared with
both COBRA groups (both P’s <0.001), whereas N-
glycan peak 6 was higher compared with COBRA HIV-
positive (P¼ 0.04) but not with HIV-negative partici-
pants (P¼ 0.18).
Age advancement in HIV-positive and
HIV-negative COBRA participants and blood
donors
Biological age was significantly greater than chronologi-
cal age by a mean of 13.2 (95% CI 11.6–14.9) years in
HIV-positive COBRA participants and by 5.5 (3.8–7.2)
years in HIV-negative participants (P< 0.001 for each).
In contrast, biological age was a mean of 7.0 (4.1–9.9)
years lower than chronological age in blood donors
(P< 0.001, Fig. 1a). Whilst age advancement was greater
in both COBRA groups compared with blood donors
(P< 0.001 for each), the HIV-positive COBRA
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Fig. 1. (a) Age advancement (biological minus chronological age) in HIV-positive and HIV-negative COBRA participants and
blood donors (Ps from linear regression); (b) Correlation between age advancement and chronological age in HIV-positive and
HIV-negative COBRA participants and blood donors (no interaction between chronological age and HIV-status/group,
PU0.66). BD, blood donors; COBRA, Co-morBidity in Relation to AIDS.participants also demonstrated greater age advancement
than the HIV-negative participants (P< 0.001). Age
advancement was also negatively correlated with chro-
nological age (Pearson’s r¼0.17, P¼ 0.08) with no
significant interaction with HIV-status/group (P¼ 0.66,
Fig. 1b).
Factors associated with age advancement
Across the entire study population, no significant
associations were found between age advancement and
ethnicity, sexual orientation or lifestyle factors (Table 2).
Overall, men had greater age advancement than women
even after adjustment for HIV-status/group. However,
among COBRA participants only, the difference (95%
CI) between men and women was only 0.09 (5.04 to
5.22) years (P¼ 0.97) and the difference between
COBRA groups and blood donors remained significant
even after adjusting for sex (both Ps <0.001). Viral co-
infections such as CMV and chronic HBV, as well as
CD4þ and CD8þT-cell count and their ratio appeared to
be associated with increased age advancement. However,
only chronic HBV, total and high avidity anti-CMV IgG
antibody titer and CD8þ T-cell count showed significant
associations, which were also independent of HIV-status/
group.
In multivariable analysis including significant factors after
adjusting for HIV-status/group (P< 0.1), the average
increase in age advancement (95% CI) remained
significant for chronic HBV [10.05 (3.45–16.64) years,
P¼ 0.003], total anti-CMV IgG antibody titer [1.83
(0.51– 3.15) years per one log (AU) increase, P¼ 0.007]
and CD8þ T cell [0.44 (0.02–0.85) years per 100 cells/ml
increase, P¼ 0.04]. Even after adjusting for chronic HBV,total anti-CMV IgG and CD8þ T-cell, HIV-positive
COBRA participants exhibited a greater age advance-
ment compared with both the HIV-negative participants
[mean increase (95% CI) 4.5 (1.6–7.5), P¼ 0.003] and
blood donors [mean increase (95% CI): 19.0 (12.6–25.4),
P< 0.001], with the HIV-negative COBRA participants
also exhibiting greater age advancement than blood
donors [mean increase (95% CI) 13.5 (7.1–20.0,
P< 0.001].
Associations with HIV parameters and exposure
to antiretroviral drugs
Among the HIV-positive participants in COBRA, in
univariable regression analyses, positive correlations were
found between age advancement and time since HIV
diagnosis, duration of antiretroviral therapy and nadir
CD4þ T-cell count <200 cells/ml (Table 3). Cumulative
exposure and/or prior exposure to some antiretroviral
drugs was also associated with an increased age
advancement (Supplementary Table 4, http://links.lww.-
com/QAD/B389); in particular each additional year of
exposure to saquinavir was associated with a 1.39 (95%
CI 0.71–2.07) years increase in age advancement
(P< 0.001), but also prior exposure to stavudine or
any d-drug were associated with greater age advancement
(P¼ 0.02 and P¼ 0.03, respectively). Due to the strong
correlations between these factors, we ran a multivariable
regression analysis with all HIV-parameters and exposures
to antiretroviral drugs that were significantly associated
with age advancement in univariable analysis (P< 0.1),
also accounting for chronic HBV, total anti-CMV IgG
antibody titer and CD8þ T-cell count. In this multivari-
able analysis, only cumulative exposure to saquinavir
(average increase of 1.17 (0.49, 1.85) years per year of
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Table 2. Mean (95% confidence interval) increase (if positive) or decrease (if negative) in age advancement among HIV-positive and HIV-
negative COBRA participants and blood donors (combined), unadjusted, and adjusted for HIV status/group.
Mean (95% CI) increase/decrease (years)
Variable Unadjusted P Adjusted for HIV status/group P
Age (per 5 years) 0.17 (0.35 to 0.02) 0.08 0.11 (0.26 to 0.04) 0.15
Gender: male vs. female 4.19 (0.01–8.36) 0.05 4.55 (0.92–8.18) 0.01
Ethnicity: black-African vs. white 3.40 (1.28 to 8.09) 0.15 1.18 (3.21 to 5.56) 0.60
Sexuality: MSM vs. non-MSM 0.92 (1.86 to 3.69) 0.51 0.01 (3.23 to 3.20) 0.99
Smoking: current smoker vs. never smoked 2.46 (0.95 to 5.88) 0.16 1.47 (1.69 to 4.64) 0.36
Ex-smoker vs. never smoked 0.71 (2.41 to 3.83) 0.65 0.28 (3.18 to 2.62) 0.85
Alcohol: current drinker vs. never drunk 1.80 (6.81 to 3.21) 0.48 0.58 (5.24 to 4.08) 0.81
Previous drinker vs. never drunk 0.60 (5.57 to 7.16) 0.81 0.03 (5.93 to 8.87) 0.99
Recreational drugs use 0.88 (3.77 to 2.01) 0.55 1.80 (4.48 to 0.87) 0.18
Chronic HBV infection 14.47 (6.12– 22.83) <0.001 9.11 (2.41–15.82) 0.008
Chronic HCV infection 6.50 (3.50–16.50) 0.20 1.09 (6.89 to 9.08) 0.79
CMV infection 11.46 (8.18–14.73) <0.001 0.54 (3.11 to 4.19) 0.77
Total anti-CMV IgG [per 1 log (AU)] 3.49 (2.15–4.85) <0.001 2.05 (0.73–3.36) 0.002
High avidity anti-CMV IgG (per 1 AU) 0.06 (0.03–0.09) <0.001 0.04 (0.01–0.07) 0.01
CD4þ T-cell count (per 100 cells/ml) 0.85 (1.30 to 0.41) <0.001 0.31 (0.79 to 0.17) 0.21
CD8þ T-cell count (per 100 cells/ml) 0.91 (0.53–1.28) <0.001 0.49 (0.07–0.90) 0.02
CD4þ : CD8þ T-cell count ratio (per 1-unit) 2.87 (4.08 to 1.66) <0.001 1.11 (2.59 to 0.38) 0.14
Blood donors were included only in analyses concerning age, sex, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection,
cytomegalovirus (CMV) infection and anti-CMV IgG. Estimates were obtained with separate linear regression models (one for each factor
considered).exposure, P< 0.001) and nadir CD4þ T-cell count less
than 200 cells/ml (average increase of 3.00 (0.22 to 6.22)
years, P¼ 0.07), as well as chronic HBV (7.35 (0.42–
14.29) years, P¼ 0.04) and total anti-CMV IgG antibody
titer (1.86 (0.22–3.51) years per one log increase,
P¼ 0.03), retained their significant associations.Discussion
Both successfully treated PLWH and people without HIV
with similar lifestyles show signs of age advancement
compared with healthy blood donors who, conversely,
appear younger than their chronological age. This may be
explained by the strict requirements around blood
donation in the Netherlands. This hypothesis is
supported, for example, by the observation that the
prevalence of CMV infection was higher in HIV-negative
participants (79.8%), and lower in blood donors (22.9%),
than in the general Dutch population (50% prevalence at
50 years of age) [27].Table 3. Mean (95% confidence interval) increase (if positive) or decrea
participants associated with each HIV-related factor.
Variable Me
Years since HIV diagnosis (per year)
Duration of antiretroviral therapy (per year)
Nadir CD4þ T-cell count (per 100 cells/ml)
Nadir CD4þ T-cell count less than 200 cells/ml
Prior AIDS
Estimates were obtained with separate linear regression models (one for each
Relation to AIDS.Whilst both groups of COBRA participants exhibited
age advancement, this was significantly greater in HIV-
positive than in HIV-negative participants. Whilst this
difference in age advancement did not appear to be
explained by differences in participant characteristics,
chronic viral co-infections such as CMV and HBV,
prior immunosuppression and exposure to some
antiretroviral drugs may have contributed to this age
advancement. CMV and HBV co-infections may cause
premature aging of the immune system in PLWH by
their chronic antigenic stimulation, inducing systemic
immune activation [28]. In particular, CMV reactiva-
tion and concurrent immune responses to control
infection are associated with aging and increased
morbidity and mortality in both the general population
and PLWH [29,30]. In the same group of people
reported here, we previously found that increased anti-
CMV IgG levels are associated with a higher
proportion of terminally differentiated CD4þ and
CD8þ T cells as well as CD4þ T-cell activation [31],
which may, in turn, have contributed to the observed
greater age advancement.se (if negative) in age advancement among HIV-positive COBRA
an (95% CI) increase/decrease (in years) P
0.28 (0.01–0.56) 0.05
0.25 (0.01–0.49) 0.05
0.73 (1.87–0.41) 0.21
3.48 (0.14–6.83) 0.04
1.70 (1.85–5.24) 0.35
factor considered). CI, confidence interval; COBRA, Co-morbidity in
Biomarkers of aging in PLWH De Francesco et al. 265Interestingly, current or past smoking did not appear to
affect age advancement. Whilst more direct and accurate
measures of smoking (including duration and frequency
of smoking) would be more appropriate to evaluate the
effect on the aging process, we cannot exclude that our
findings reflect a lack of association with markers used in
this study, especially in cohorts with relatively low
smoking frequency (COBRA participants who self-
reported current smoking, reported a mean of 12
cigarettes smoked per day). Other factors that have been
shown to be associated with different aspects of the aging
process of PLWH in previous studies (i.e. HCV co-
infection [32] and CD4þ : CD8þ T-cell count ratio [33])
were not linked to greater age advancement. Whilst this is
likely to be because of a combination of low statistical
power (only five participants were infected with chronic
HCV) and collinearity with other lifestyle factors (e.g.
recreational drugs for HCV and CD8þ T-cell count for
CD4þ : CD8þ ratio), further studies are needed to
elucidate potential contributors to the age advancement
seen in PLWH.
Among antiretroviral drugs, we found a significant
association between age advancement and duration of
past exposure to saquinavir, which was independent of
concomitant exposure to other drugs generally consid-
ered to have the greatest mitochondrial toxicities and
potential effects on aging such as didanosine, stavudine,
zalcitabine and zidovudine (data not shown). Whereas
saquinavir has been shown to directly induce vascular
endothelial toxicity in vitro [34], other HIV protease
inhibitors were shown to be able to induce vascular
smooth muscle cell senescence by downregulating
ZMPSTE24, leading to prelamin A accumulation and
potential premature vascular aging, changes, which were
also observed in peripheral blood mononuclear cells from
HIV-infected patients who were treated with the same
protease inhibitors [35]. The reason why we only
observed an association between age advancement and
exposure to saquinavir, but not other HIV protease
inhibitors, remains unclear, and suggests this observation
should be interpreted with caution. Importantly, having
experienced more pronounced immunodeficiency in
HIV-positive participants was also linked to an increased
age advancement suggesting that a greater effect on aging
is likely to occur as the infection remains untreated
for longer.
Our findings are consistent with previous reports of brain
aging in the COBRA study [18] and with other studies of
cellular and molecular markers of biological aging.
Indeed, studies of telomere length and CDKN2A [14,36],
CD8þ T-cell senescence [37], and DNA methylation
profiles (’epigenetic clock’) [16,38] showed similar
indications of age advancement in PLWH. Other studies
reported evidence of accentuated aging only in PLWH
with low nadir CD4þ T-cell counts compared with HIV-
negative individuals [39,40]. Of note, however, theseprevious studies often included untreated PLWH (some
with detectable HIV RNA) and HIV-negative controls
that differed with regards to some lifestyle behaviors, such
as smoking and alcohol consumption. In our study,
effectively treated PLWH with high CD4þ T-cell counts
and highly comparable HIV-negative controls were
purposely recruited in order to reduce the influence of
sociodemographic and lifestyle confounding factors. The
importance of an appropriately chosen control group of
HIV-negative individuals is also highlighted by the
finding that HIV-negative COBRA participants showed
greater age advancement compared with blood donors.
Furthermore, these studies only focus on one single tissue
or body system, and are therefore unable to reflect the
intrinsic multicausal and multisystem nature of the aging
process [41]. Chronic HIV may differently affect the rate
of aging at the levels of cells, tissues or body systems
within the same organism and this complexity is more
likely reflected by a method used in our study, which
integrates multiple sources of molecular, cellular and
physiologic data.
Age advancement reflects the difference in body function
and composition of an individual relative to that of a
similarly-aged ‘healthy’ individual. As such, it is not
surprising that we found a weak negative correlation with
chronological age that, if anything, may reflect survivor-
ship bias. Moreover, as we found no interaction between
the correlation of age advancement with chronological
age and HIV-status/group, our results are more suggestive
of accentuated rather than accelerated aging in the
context of treated HIV disease. However, longitudinal
follow-up is required to more appropriately address this
issue. Accentuated aging occurs when there is an
increased burden of aging-related damage but the year-
on-year damage remains static over time whereas
accelerated aging occurs when the decline arises earlier
than expected and implies a progressive increase in the
rate of decline [42].
Unmeasured confounders (e.g. living settings (urban vs.
rural), diet, physical activity, sleep habits and direct, rather
than self-reported, information on smoking and sub-
stance/alcohol use) may also have contributed to the
increased age advancement we observed in both PLWH
and lifestyle-matched HIV-negative individuals and also
to the apparent increase due to HIV. Our study has further
limitations. Given the cross-sectional design, it can only
assess associations and longitudinal studies would be
necessary to evaluate the potential causal role of HIVand
the interplay with antiretroviral drugs and viral co-
infections. The sample size was believed to be sufficient to
allow meaningful analysis; however, the study may not be
powered enough to evaluate associations with cumulative
exposure to antiretroviral drugs as they were evaluated
only on participants with prior exposure to a drug. Also
our cohort predominantly constitutes white, northern
European MSM over the age of 45 years. Results may,
266 AIDS 2019, Vol 33 No 2therefore, not be generalizable to younger populations or
populations within a different HIVepidemic setting. Also,
individuals with major depression were excluded from the
study; as psychological stress has been linked with
molecular changes that can affect the aging process [43],
this could have resulted in an underestimation of age
advancement in both COBRA groups. Finally, the age
advancement observed in PLWH, COBRA HIV-nega-
tive individuals and blood donors is relative to the
population used by the MARK-AGE project to develop
the algorithm to estimate biological age. Individuals with
self-reported HIV, HBV (except seropositivity by
vaccination), HCV or cancer were excluded but the
representativeness of the sample to European countries
involved in the MARK-AGE study still needs to be
assessed. Whilst the algorithm has not been yet validated
in external population (including cohort of PLWH), it
showed promising results in individuals affected by
Down’s syndrome who, as expected, showed greater age
advancement compared with the general population
(manuscript in preparation). Moreover, sensitivity analysis
in our cohort suggest a positive correlation between age
advancement and the number of age-associated comor-
bidities (Pearson’s r¼ 0.18, P¼ 0.007) and time needed to
walk 15 feet (Pearson’s r¼ 0.13, P¼ 0.04) as well as a
negative correlation with hand grip (Pearson’s r¼0.12,
P¼ 0.05), a validated measure of frailty.
In conclusion, our results suggest that PLWH with
undetectable plasma HIV RNA may experience accen-
tuated aging compared with HIV-negative individuals
with similar lifestyles, as estimated using a set of validated
biomarkers of aging. This age advancement appears to be
related to viral co-infections such as CMV and chronic
HBV, but also to historic severe immunosuppression and
possibly exposure to particular antiretroviral drugs. Future
longitudinal studies are required to further help clarifying
the effect of HIV and its treatment on the natural aging
process and the functional and clinical consequences in
the millions of PLWH worldwide.Acknowledgements
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